Could This Be Moderna's Ticket to Long-Term Success?
Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. Initially, the company aimed to win the regulatory nod for use in teens last year. But reports of heart inflammation in some young adults who had received the Moderna vaccine spurred the U.S. Food and Drug Administration (FDA) to take more time reviewing the company's submission.
This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success? Let's find out.
It's important to note that regulators also authorized rival Pfizer's (NYSE: PFE) vaccine for use in kids six months through age 4 this month. Last year the FDA authorized Pfizer's vaccine for use in older children, so Moderna isn't the only player in this market.
Source Fool.com
